Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

M. Fassnacht, A. Berruti, E. Baudin, M.J. Demeure, J. Gilbert, H. Haak, M. Kroiss, D.I. Quinn, E. Hesseltine, C.L. Ronchi, M. Terzolo, T.K. Choueiri, S. Poondru, T. Fleege, R. Rorig, J. Chen, A.W. Stephens, F. Worden, G.D. Hammer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study'. Together they form a unique fingerprint.

Keyphrases

INIS

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science